Trial Profile
Regress-HFPEF: Regression of Fibrosis & Reversal of Diastolic Dysfunction in HFPEF Patients Treated With Allogeneic CDCs
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs CAP-1002 (Primary)
- Indications Chronic heart failure
- Focus Adverse reactions
- Acronyms Regress-HFpEF
- 28 Aug 2023 Status changed from active, no longer recruiting to completed.
- 15 Dec 2022 Planned End Date changed from 1 Nov 2022 to 1 Feb 2023.
- 15 Dec 2022 Planned primary completion date changed from 1 Nov 2022 to 1 Feb 2023.